HRP20100673T1 - Smanjivanje potencijalnih jatrogenskih rizika povezanih s cjepivima protiv gripe - Google Patents
Smanjivanje potencijalnih jatrogenskih rizika povezanih s cjepivima protiv gripe Download PDFInfo
- Publication number
- HRP20100673T1 HRP20100673T1 HR20100673T HRP20100673T HRP20100673T1 HR P20100673 T1 HRP20100673 T1 HR P20100673T1 HR 20100673 T HR20100673 T HR 20100673T HR P20100673 T HRP20100673 T HR P20100673T HR P20100673 T1 HRP20100673 T1 HR P20100673T1
- Authority
- HR
- Croatia
- Prior art keywords
- virus
- degree
- vaccine
- culture
- infectious agent
- Prior art date
Links
- 229960003971 influenza vaccine Drugs 0.000 title claims 2
- 230000003247 decreasing effect Effects 0.000 title 1
- 230000000642 iatrogenic effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract 7
- 229960005486 vaccine Drugs 0.000 claims abstract 6
- 244000052769 pathogen Species 0.000 claims abstract 5
- 210000004027 cell Anatomy 0.000 claims abstract 3
- 238000012360 testing method Methods 0.000 claims abstract 3
- 210000003501 vero cell Anatomy 0.000 claims abstract 2
- 241000700605 Viruses Species 0.000 claims 6
- 241000709661 Enterovirus Species 0.000 claims 3
- 241000709664 Picornaviridae Species 0.000 claims 3
- 238000001514 detection method Methods 0.000 claims 3
- 239000012678 infectious agent Substances 0.000 claims 3
- 241000342334 Human metapneumovirus Species 0.000 claims 2
- 241000711504 Paramyxoviridae Species 0.000 claims 2
- 241000725643 Respiratory syncytial virus Species 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 241000282465 Canis Species 0.000 claims 1
- 241000606161 Chlamydia Species 0.000 claims 1
- 241001647372 Chlamydia pneumoniae Species 0.000 claims 1
- 241001647378 Chlamydia psittaci Species 0.000 claims 1
- 241000606153 Chlamydia trachomatis Species 0.000 claims 1
- 241001533384 Circovirus Species 0.000 claims 1
- 241000711573 Coronaviridae Species 0.000 claims 1
- 241000709687 Coxsackievirus Species 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 241001466953 Echovirus Species 0.000 claims 1
- 241000287828 Gallus gallus Species 0.000 claims 1
- 244000309467 Human Coronavirus Species 0.000 claims 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims 1
- 241000829111 Human polyomavirus 1 Species 0.000 claims 1
- 241000701460 JC polyomavirus Species 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 108010052285 Membrane Proteins Proteins 0.000 claims 1
- 102000018697 Membrane Proteins Human genes 0.000 claims 1
- 241000351643 Metapneumovirus Species 0.000 claims 1
- 241000711386 Mumps virus Species 0.000 claims 1
- 241000711904 Pneumoviridae Species 0.000 claims 1
- 241000125945 Protoparvovirus Species 0.000 claims 1
- 241000702247 Reoviridae Species 0.000 claims 1
- 241000702670 Rotavirus Species 0.000 claims 1
- 241001533467 Rubulavirus Species 0.000 claims 1
- 241000315672 SARS coronavirus Species 0.000 claims 1
- 241000282898 Sus scrofa Species 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 238000010790 dilution Methods 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- 235000013601 eggs Nutrition 0.000 claims 1
- 230000000984 immunochemical effect Effects 0.000 claims 1
- 230000002779 inactivation Effects 0.000 claims 1
- 238000011081 inoculation Methods 0.000 claims 1
- 210000001161 mammalian embryo Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 238000000751 protein extraction Methods 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 229940031418 trivalent vaccine Drugs 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000011109 contamination Methods 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04255471 | 2004-09-09 | ||
| PCT/IB2005/003266 WO2006027698A1 (en) | 2004-09-09 | 2005-09-09 | Decreasing potential iatrogenic risks associated with influenza vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100673T1 true HRP20100673T1 (hr) | 2011-02-28 |
Family
ID=35520177
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100673T HRP20100673T1 (hr) | 2004-09-09 | 2010-12-06 | Smanjivanje potencijalnih jatrogenskih rizika povezanih s cjepivima protiv gripe |
| HR20110007T HRP20110007T1 (hr) | 2004-09-09 | 2011-01-05 | Smanjivanje potencijalnih jatrogenskih rizika povezanih s cjepivima protiv gripe |
| HRP20120640TT HRP20120640T1 (hr) | 2004-09-09 | 2012-08-07 | Smanjenje potencijalnih jatrogenih rizika vezanih uz cjepiva protiv gripe |
| HRP20130962TT HRP20130962T1 (hr) | 2004-09-09 | 2013-10-10 | Smanjenje potencijalnih iatrogenih rizika povezanih sa antigenima cjepiva |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110007T HRP20110007T1 (hr) | 2004-09-09 | 2011-01-05 | Smanjivanje potencijalnih jatrogenskih rizika povezanih s cjepivima protiv gripe |
| HRP20120640TT HRP20120640T1 (hr) | 2004-09-09 | 2012-08-07 | Smanjenje potencijalnih jatrogenih rizika vezanih uz cjepiva protiv gripe |
| HRP20130962TT HRP20130962T1 (hr) | 2004-09-09 | 2013-10-10 | Smanjenje potencijalnih iatrogenih rizika povezanih sa antigenima cjepiva |
Country Status (16)
| Country | Link |
|---|---|
| US (6) | US8119337B2 (de) |
| EP (5) | EP1789084B1 (de) |
| JP (7) | JP2008512443A (de) |
| AT (2) | ATE488248T1 (de) |
| CA (2) | CA2890962A1 (de) |
| CY (3) | CY1111180T1 (de) |
| DE (3) | DE602005024827D1 (de) |
| DK (4) | DK1789084T3 (de) |
| ES (4) | ES2357747T3 (de) |
| HK (2) | HK1105364A1 (de) |
| HR (4) | HRP20100673T1 (de) |
| PL (4) | PL2578229T3 (de) |
| PT (4) | PT2578229E (de) |
| RS (3) | RS51721B (de) |
| SI (4) | SI2236155T1 (de) |
| WO (1) | WO2006027698A1 (de) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602005024827D1 (de) | 2004-09-09 | 2010-12-30 | Novartis Vaccines & Diagnostic | Verminderung von potentiellen iatrogenen risiken in verbindung mit influenza impfstoffen |
| ES2310062B1 (es) | 2005-07-15 | 2009-11-13 | Bionostra, S.L. | Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones. |
| CN101365480B (zh) * | 2005-11-01 | 2014-11-05 | 诺华疫苗和诊断有限两合公司 | 经由β-丙内酯处理的残留细胞DNA水平降低的细胞衍生病毒疫苗 |
| CA2628152C (en) | 2005-11-04 | 2016-02-02 | Novartis Vaccines And Diagnostics S.R.L. | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
| US20110180430A1 (en) | 2005-11-04 | 2011-07-28 | Novartis Vaccines And Diagnostics Srl | Adjuvanted influenza vaccines including cytokine-inducing agents |
| JP2009514844A (ja) | 2005-11-04 | 2009-04-09 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | スプリットインフルエンザワクチン用のアジュバントとしての遊離水相界面活性剤を含むエマルション |
| WO2007052155A2 (en) | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics Srl | Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant |
| CN102727885A (zh) | 2005-11-04 | 2012-10-17 | 诺华疫苗和诊断有限公司 | 包含颗粒佐剂和免疫增强剂组合的流感疫苗 |
| KR20110110853A (ko) | 2006-01-27 | 2011-10-07 | 노파르티스 파르마 아게 | 적혈구응집소 및 기질 단백질을 함유한 인플루엔자 백신 |
| CA2646349A1 (en) | 2006-03-24 | 2007-10-04 | Novartis Vaccines And Diagnostics Gmbh & Co Kg | Storage of influenza vaccines without refrigeration |
| WO2007126810A2 (en) | 2006-03-31 | 2007-11-08 | Warf - Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses for vaccines |
| GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
| EP3456348A1 (de) | 2006-09-11 | 2019-03-20 | Seqirus UK Limited | Herstellung von influenza-virus-impfstoffen ohne verwendung von eiern |
| WO2008059018A2 (en) * | 2006-11-15 | 2008-05-22 | Intervet International B.V. | Vaccine for vaccinating felines and canines against influenza virus |
| CA2671629C (en) | 2006-12-06 | 2017-08-15 | Novartis Ag | Vaccines including antigen from four strains of influenza virus |
| US9474798B2 (en) | 2007-06-18 | 2016-10-25 | Wisconsin Alumni Research Foundation | Influenza M2 protein mutant viruses as live influenza attenuated vaccines |
| CA2692200A1 (en) | 2007-06-27 | 2008-12-31 | Novartis Ag | Low-additive influenza vaccines |
| GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
| AU2009227674C1 (en) | 2008-03-18 | 2015-01-29 | Seqirus UK Limited | Improvements in preparation of influenza virus vaccine antigens |
| JP2012507272A (ja) | 2008-11-05 | 2012-03-29 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 新規な方法 |
| PL2396032T3 (pl) | 2009-02-10 | 2017-05-31 | Seqirus UK Limited | Szczepionki przeciw grypie o obniżonych zawartościach skwalenu |
| CA2752041A1 (en) | 2009-02-10 | 2010-08-19 | Novartis Ag | Influenza vaccines with increased amounts of h3 antigen |
| CA2752039A1 (en) | 2009-02-10 | 2010-08-19 | Novartis Ag | Influenza vaccine regimens for pandemic-associated strains |
| BE1019643A3 (fr) | 2009-04-27 | 2012-09-04 | Novartis Ag | Vaccins de protection contre la grippe. |
| EP2475385A1 (de) | 2009-09-10 | 2012-07-18 | Novartis AG | Kombinationsimpfstoffe gegen atemwegserkrankungen |
| JP2013507990A (ja) | 2009-10-26 | 2013-03-07 | ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション | ベロ細胞において増強された複製を有する高力価の組換えインフルエンザウイルス |
| US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
| CA2797059A1 (en) * | 2010-05-03 | 2011-11-10 | Glaxosmithkline Biologicals S.A. | Novel method |
| WO2011145081A1 (en) | 2010-05-21 | 2011-11-24 | Novartis Ag | Influenza virus reassortment method |
| PL2575873T3 (pl) | 2010-06-01 | 2016-06-30 | Novartis Ag | Zatężanie i liofilizacja antygenów szczepionkowych grypy |
| PL2575872T3 (pl) | 2010-06-01 | 2021-02-22 | Seqirus UK Limited | Zatężanie antygenów szczepionkowych grypy bez liofilizacji |
| GB201011502D0 (en) | 2010-07-08 | 2010-08-25 | Glaxosmithkline Biolog Sa | Novel process |
| EP2605792B1 (de) | 2010-08-20 | 2014-12-10 | Novartis AG | Lösliche nadelfelder zur freisetzung von grippeimpfstoffen |
| WO2012032482A1 (en) | 2010-09-07 | 2012-03-15 | Novartis Ag | Generic assays for detection of mammalian reovirus |
| EP2678452B1 (de) | 2011-02-25 | 2016-02-24 | Novartis AG | Exogene interne positivkontrolle zur viruserkennung |
| WO2013057715A1 (en) | 2011-10-20 | 2013-04-25 | Novartis Ag | Adjuvanted influenza b virus vaccines for pediatric priming |
| US20140335507A1 (en) * | 2011-12-12 | 2014-11-13 | Novartis Ag | Assays for influenza virus hemagglutinins |
| GB201218195D0 (en) | 2012-10-10 | 2012-11-21 | Istituto Zooprofilattico Sperimentale Delle Venezie | Composition |
| EP3022296B1 (de) | 2013-07-15 | 2022-12-28 | Wisconsin Alumni Research Foundation | Rekombinante influenzaviren mit hohem titer und erhöhter replikation in mdck- oder vero-zellen oder eiern |
| WO2015118146A1 (en) | 2014-02-10 | 2015-08-13 | Univercells Nv | System, apparatus and method for biomolecules production |
| RU2628800C2 (ru) * | 2014-03-12 | 2017-08-22 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Амидные соединения, способы получения, применение в качестве средств для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами |
| WO2015196150A2 (en) | 2014-06-20 | 2015-12-23 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
| AR102547A1 (es) | 2014-11-07 | 2017-03-08 | Takeda Vaccines Inc | Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso |
| AR102548A1 (es) | 2014-11-07 | 2017-03-08 | Takeda Vaccines Inc | Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso |
| US10633422B2 (en) | 2015-06-01 | 2020-04-28 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA |
| US11013795B2 (en) | 2015-06-26 | 2021-05-25 | Seqirus UK Limited | Antigenically matched influenza vaccines |
| US9890363B2 (en) | 2015-07-06 | 2018-02-13 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication for vaccine development |
| JP6830070B2 (ja) | 2015-07-07 | 2021-02-17 | セキラス ユーケー リミテッドＳｅｑｉｒｕｓ ＵＫ Ｌｉｍｉｔｅｄ | インフルエンザ効力アッセイ |
| US11197925B2 (en) | 2016-02-19 | 2021-12-14 | Wisconsin Alumni Research Foundation (Warf) | Influenza B virus replication for vaccine development |
| US11648304B2 (en) | 2017-11-03 | 2023-05-16 | Takeda Vaccines, Inc. | Zika vaccines and immunogenic compositions, and methods of using the same |
| JP2022514112A (ja) * | 2018-10-15 | 2022-02-09 | リジェネクスバイオ インコーポレイテッド | 複製欠損型ウイルスベクター及びウイルスの感染性を測定するための方法 |
| EP3914295A2 (de) | 2019-01-23 | 2021-12-01 | Yoshihiro Kawaoka | Mutationen zur verleihung von genetischer stabilität gegenüber zusätzlichen genen bei grippeviren |
| CN113874496A (zh) | 2019-02-08 | 2021-12-31 | 威斯康星校友研究基金会(Warf) | 人源化细胞系 |
| CN114929269A (zh) | 2019-05-01 | 2022-08-19 | 威斯康星校友研究基金会(Warf) | 用于疫苗开发的改进的流感病毒复制 |
| KR20220007077A (ko) | 2019-05-08 | 2022-01-18 | 다케다 백신즈 인코포레이티드 | 불활성화 바이러스 조성물 및 지카 백신 제형 |
| WO2021041624A2 (en) | 2019-08-27 | 2021-03-04 | Yoshihiro Kawaoka | Recombinant influenza viruses with stabilized ha for replication in eggs |
| JP2023502650A (ja) | 2019-11-18 | 2023-01-25 | セキラス ピーティーワイ リミテッド | 遺伝子再集合インフルエンザウイルスを産生するための方法 |
| EP4093415A1 (de) * | 2020-01-24 | 2022-11-30 | Wisconsin Alumni Research Foundation (WARF) | Rekombinante influenza-viren mit stabilisiertem na |
| WO2022187230A2 (en) * | 2021-03-01 | 2022-09-09 | Iowa State University Research Foundation, Inc. | Methods and compositions for detecting and producing porcine morbillivirus and immunogenic compositions thereof |
| CN114107392A (zh) * | 2021-11-22 | 2022-03-01 | 昆明理工大学 | 一种cvb5病毒类病毒样颗粒的制备方法 |
| WO2023154043A1 (en) | 2022-02-09 | 2023-08-17 | Takeda Vaccines, Inc. | Zika vaccines and immunogenic compositions, and methods of using the same |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4193991A (en) * | 1978-12-20 | 1980-03-18 | Cornell Research Foundation, Inc. | Canine parvovirus vaccine |
| EP0261955A3 (de) * | 1986-09-26 | 1989-06-07 | E.I. Du Pont De Nemours And Company | Verfahren zur Immobilisierung von DNS |
| US6284492B1 (en) * | 1988-02-26 | 2001-09-04 | Large Scale Biology Corporation | Recombinant animal viral nucleic acids |
| NZ240369A (en) | 1990-10-30 | 1993-09-27 | Daiichi Seiyaku Co | Muramyl dipeptide derivatives and vaccine compositions |
| JPH0813753B2 (ja) * | 1992-05-22 | 1996-02-14 | 株式会社微生物化学研究所 | 牛伝染性鼻気管炎ウイルス感染症、牛ウイルス性下痢−粘膜病ウイルス感染症、パラインフルエンザ３型ウイルス感染症、牛ｒｓウイルス感染症および牛アデノ７型ウイルス感染症５種混合生ワクチン |
| IL103939A (en) * | 1992-12-01 | 1996-09-12 | Abic Ltd | An anti-DBI vaccine in birds containing attenuated live DBI virus |
| EP0684838A1 (de) | 1993-02-19 | 1995-12-06 | Smithkline Beecham Corporation | 3-0-deacylierte monophoshoryl lipid a enthaltende influenzaimpfstoffzusammensetzungen |
| DE4311580C1 (de) * | 1993-04-12 | 1994-08-18 | Werner Prof Dr Med Reutter | Glycoproteine, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Mittel |
| US5824536A (en) * | 1994-08-23 | 1998-10-20 | St. Jude Children's Research Hospital | Influenza virus replicated in mammalian cell culture and vaccine production |
| EP2290053A1 (de) | 1994-11-10 | 2011-03-02 | Baxter Healthcare S.A. | Verfahren zur Herstellung von Influenzaviren in protein-freiem Zellkulturmedium |
| US6146873A (en) * | 1994-11-10 | 2000-11-14 | Baxter Aktiengesellschaft | Production of orthomyxoviruses in monkey kidney cells using protein-free media |
| GB9500788D0 (en) | 1995-01-16 | 1995-03-08 | Medeva Holdings Bv | Vaccine compositions |
| DE19612967A1 (de) * | 1996-04-01 | 1997-10-02 | Behringwerke Ag | Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren |
| DE19612966B4 (de) | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
| TW570803B (en) | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
| JPH1175833A (ja) * | 1997-06-23 | 1999-03-23 | Chemo Sero Therapeut Res Inst | トリレオウイルスの調製法 |
| GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
| RU2000118777A (ru) | 1997-12-11 | 2002-07-10 | Университи Оф Саскачеван (Ca) | Вирус синдрома мультисистемного истощения свиньи у поросят-отъемышей |
| GB9804632D0 (en) * | 1998-03-05 | 1998-04-29 | Cantab Pharma Res | Virus preparations and methods |
| AT408615B (de) | 1998-09-15 | 2002-01-25 | Immuno Ag | Neue influenzavirus-impfstoffzusammensetzung |
| US6855544B1 (en) * | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
| GB9923176D0 (en) | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
| EP1103610A1 (de) * | 1999-11-26 | 2001-05-30 | Introgene B.V. | Impfstoffherstellung von immortalisierten Säugetierzellinien |
| US7192759B1 (en) * | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
| DOP2000000109A (es) * | 1999-12-23 | 2002-08-30 | Gerald Kleymann | Derivados de tiazolilamida |
| TWI228420B (en) | 2001-05-30 | 2005-03-01 | Smithkline Beecham Pharma Gmbh | Novel vaccine composition |
| DE10144906B4 (de) | 2001-09-12 | 2013-11-28 | Novartis Vaccines And Diagnostics Gmbh | Verfahren zur großtechnischen Herstellung von Impfstoffen |
| DE10144903A1 (de) * | 2001-09-12 | 2003-03-27 | Chiron Behring Gmbh & Co | Vermehrung von Viren in Zellkultur |
| FR2836924B1 (fr) | 2002-03-08 | 2005-01-14 | Vivalis | Lignees de cellules aviaires utiles pour la production de substances d'interet |
| CN1678345A (zh) * | 2002-04-26 | 2005-10-05 | 米迪缪尼疫苗股份有限公司 | 制备流感病毒的多质粒系统 |
| DE10221836A1 (de) * | 2002-05-16 | 2003-12-04 | Lohmann Animal Health Gmbh | Attenuierung von Metapneumovirus |
| WO2004005493A1 (en) * | 2002-07-09 | 2004-01-15 | Baxter International, Inc. | Animal protein free media for cultivation of cells |
| JP3957188B2 (ja) * | 2002-10-25 | 2007-08-15 | ▲あき▼夫 友田 | 抗ウィルス剤 |
| CA2514653A1 (en) | 2003-01-30 | 2004-08-12 | Medimmune, Inc. | Uses of integrin alphavbeta3 antagonists |
| CN101410519B (zh) * | 2003-04-25 | 2013-04-24 | 免疫医疗有限责任公司 | 间质肺病毒株及其在疫苗制剂中以及用作抗原性序列表达载体的用途和繁殖病毒的方法 |
| EP1528101A1 (de) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalisierte Vogel-Zelllinien für die Produktion von Viren |
| DE602005024827D1 (de) | 2004-09-09 | 2010-12-30 | Novartis Vaccines & Diagnostic | Verminderung von potentiellen iatrogenen risiken in verbindung mit influenza impfstoffen |
| NZ582019A (en) | 2007-06-14 | 2012-07-27 | Univ Oklahoma State | Vaccines containing canine parvovirus genetic variants |
-
2005
- 2005-09-09 DE DE602005024827T patent/DE602005024827D1/de active Active
- 2005-09-09 DK DK05795012.3T patent/DK1789084T3/da active
- 2005-09-09 DK DK09075377T patent/DK2179744T3/da active
- 2005-09-09 PT PT121930960T patent/PT2578229E/pt unknown
- 2005-09-09 JP JP2007530801A patent/JP2008512443A/ja not_active Withdrawn
- 2005-09-09 PL PL12193096T patent/PL2578229T3/pl unknown
- 2005-09-09 RS RSP20110075 patent/RS51721B/en unknown
- 2005-09-09 DE DE2021193096 patent/DE12193096T1/de active Pending
- 2005-09-09 ES ES05795012T patent/ES2357747T3/es active Active
- 2005-09-09 EP EP05795012A patent/EP1789084B1/de active Active
- 2005-09-09 US US11/662,481 patent/US8119337B2/en not_active Expired - Fee Related
- 2005-09-09 EP EP20090075377 patent/EP2179744B1/de active Active
- 2005-09-09 RS RSP20110084 patent/RS51665B/en unknown
- 2005-09-09 ES ES09075377T patent/ES2357752T3/es active Active
- 2005-09-09 DK DK10075310T patent/DK2236155T3/da active
- 2005-09-09 DE DE200560025170 patent/DE602005025170D1/de active Active
- 2005-09-09 ES ES10075310T patent/ES2386272T3/es active Active
- 2005-09-09 CA CA2890962A patent/CA2890962A1/en not_active Abandoned
- 2005-09-09 PL PL05795012T patent/PL1789084T3/pl unknown
- 2005-09-09 AT AT05795012T patent/ATE488248T1/de active
- 2005-09-09 WO PCT/IB2005/003266 patent/WO2006027698A1/en active Application Filing
- 2005-09-09 RS RS20120317A patent/RS52400B/en unknown
- 2005-09-09 ES ES12193096T patent/ES2432655T3/es active Active
- 2005-09-09 PL PL10075310T patent/PL2236155T3/pl unknown
- 2005-09-09 PL PL09075377T patent/PL2179744T3/pl unknown
- 2005-09-09 AT AT09075377T patent/ATE489965T1/de active
- 2005-09-09 PT PT09075377T patent/PT2179744E/pt unknown
- 2005-09-09 SI SI200531559T patent/SI2236155T1/sl unknown
- 2005-09-09 PT PT05795012T patent/PT1789084E/pt unknown
- 2005-09-09 PT PT10075310T patent/PT2236155E/pt unknown
- 2005-09-09 EP EP20100075310 patent/EP2236155B1/de not_active Revoked
- 2005-09-09 EP EP20120193096 patent/EP2578229B1/de not_active Revoked
- 2005-09-09 SI SI200531776T patent/SI2578229T1/sl unknown
- 2005-09-09 EP EP12157945.2A patent/EP2471551B1/de active Active
- 2005-09-09 SI SI200531234T patent/SI2179744T1/sl unknown
- 2005-09-09 CA CA2579859A patent/CA2579859C/en not_active Expired - Fee Related
- 2005-09-09 SI SI200531223T patent/SI1789084T1/sl unknown
- 2005-09-09 DK DK12193096T patent/DK2578229T3/da active
-
2007
- 2007-11-26 HK HK07112869.6A patent/HK1105364A1/xx not_active IP Right Cessation
-
2010
- 2010-09-30 HK HK10109406A patent/HK1144374A1/xx not_active IP Right Cessation
- 2010-12-06 HR HR20100673T patent/HRP20100673T1/hr unknown
-
2011
- 2011-01-05 HR HR20110007T patent/HRP20110007T1/hr unknown
- 2011-02-09 CY CY20111100152T patent/CY1111180T1/el unknown
- 2011-02-16 CY CY20111100197T patent/CY1111208T1/el unknown
- 2011-07-19 JP JP2011158471A patent/JP2011207911A/ja not_active Withdrawn
- 2011-10-14 US US13/274,285 patent/US9220768B2/en not_active Expired - Fee Related
- 2011-11-08 JP JP2011244904A patent/JP2012025784A/ja not_active Withdrawn
-
2012
- 2012-08-07 CY CY20121100706T patent/CY1113225T1/el unknown
- 2012-08-07 HR HRP20120640TT patent/HRP20120640T1/hr unknown
-
2013
- 2013-01-10 US US13/738,929 patent/US8460914B2/en active Active
- 2013-01-11 US US13/740,100 patent/US9358280B2/en not_active Expired - Fee Related
- 2013-02-20 JP JP2013030624A patent/JP2013100358A/ja not_active Withdrawn
- 2013-10-10 HR HRP20130962TT patent/HRP20130962T1/hr unknown
-
2015
- 2015-08-06 JP JP2015155818A patent/JP2015205929A/ja active Pending
-
2016
- 2016-05-09 US US15/150,214 patent/US10155932B2/en active Active
- 2016-11-29 JP JP2016230896A patent/JP2017057209A/ja not_active Withdrawn
-
2018
- 2018-11-08 US US16/184,482 patent/US10954493B2/en active Active
-
2019
- 2019-08-08 JP JP2019146040A patent/JP2019210292A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100673T1 (hr) | Smanjivanje potencijalnih jatrogenskih rizika povezanih s cjepivima protiv gripe | |
| World Health Organization | WHO manual on animal influenza diagnosis and surveillance | |
| Pastoret | Human and animal vaccine contaminations | |
| JP2008512443A5 (de) | ||
| JP2012025784A5 (de) | ||
| Zhang et al. | Isolation of swine influenza virus in cell cultures and embryonated chicken eggs | |
| US20080193478A1 (en) | Inactivated Poliomyelitis Vaccine Derived From Sabin Strain Of Polio Virus | |
| US20180154004A1 (en) | Non-Gelatin Vaccine Protectant Composition and Live Attenuated Influenza Vaccine | |
| Pestka et al. | Occurrence, characteristics and control of pigeon paramyxovirus type 1 in pigeons | |
| Choi et al. | Evaluation of transmission of swine influenza type A subtype H1N2 virus in seropositive pigs | |
| Zhang et al. | Isolation of swine influenza A virus in cell cultures and embryonated chicken eggs | |
| Velayudhan et al. | Human metapneumovirus in turkey poults | |
| BRPI0914805B1 (pt) | método para replicar vírus em uma cultura de células scldk, processo para adaptar células cldk dependentes do substrato para desenvolvimento em suspensão, método para propagar continuamente células scldk em suspensão, e, composição | |
| Cliquet et al. | The fluorescent antibody virus neutralization test | |
| CN107267467B (zh) | 一种猪繁殖与呼吸综合征病毒的分离方法 | |
| CN107557346B (zh) | 一株h9亚型低致病性禽流感病毒及其应用 | |
| Wang et al. | Pathogenicity, immunogenicity, and protective ability of an attenuated SARS-CoV-2 variant with a deletion at the S1/S2 junction of the spike protein | |
| Gueriche et al. | The etiological role of the parainfluenza-3 virus in the respiratory pathology of young cattle | |
| CN113049816B (zh) | 一种新城疫病毒滴度的测定方法 | |
| Aoki et al. | Isolation of vaccine-derived measles viruses from children with acute respiratory infection | |
| Namroodi et al. | Frequency and antimicrobial resistance pattern of Salmonella Spp in asymptomatic rural dogs | |
| Manzoor et al. | Pathotyping of Newcastle disease virus using multiplex reverse transcription polymerase chain reaction and pathological studies in naturally infected broiler chicks | |
| CN105779376B (zh) | 一种流感病毒分离无血清培养基及其用途和制备 | |
| JP6174857B2 (ja) | 外来物質試験 | |
| Ali et al. | World Congress on Infectious Diseases |